Wedbush began coverage on shares of Generation Bio (NASDAQ:GBIO) in a research note released on Tuesday, BenzingaRatingsTable reports. The firm issued an outperform rating and a $31.00 price objective on the stock. Wedbush also issued estimates for Generation Bio’s Q2 2020 earnings at ($0.33) EPS, Q3 2020 earnings at ($0.41) EPS, Q4 2020 earnings at ($0.53) EPS, FY2020 earnings at ($1.76) EPS, FY2021 earnings at ($2.22) EPS, FY2022 earnings at ($1.70) EPS, FY2023 earnings at ($2.08) EPS and FY2024 earnings at ($2.46) EPS.
Several other research firms have also issued reports on GBIO. Jefferies Financial Group assumed coverage on Generation Bio in a research note on Tuesday. They set a buy rating and a $38.00 price objective for the company. Cowen initiated coverage on Generation Bio in a research report on Tuesday. They set an outperform rating on the stock.
NASDAQ:GBIO opened at $19.71 on Tuesday. Generation Bio has a 1 year low of $18.51 and a 1 year high of $24.90.
Generation Bio Company Profile
Generation Bio Co develops gene therapies for the treatment of genetic diseases. It focuses in the areas of liver, eye, muscle, and brain disorders. Generation Bio Co was formerly known as Torus Therapeutics, Inc and changed its name to Generation Bio Co in November 2017. The company was founded in 2016 and is based in Cambridge, Massachusetts.
Recommended Story: Cost of Equity For A Business, Investors
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.